HLA engineering of human pluripotent stem cells.

Area of Science:

• Stem Cell Biology
• Immunology
• Genetic Engineering

Background:

• Clinical application of human pluripotent stem cells is hindered by immune rejection due to human leukocyte antigen (HLA) gene disparities.
• Developing patient-specific stem cell lines for transplantation is logistically challenging.
• Existing methods for generating histocompatible stem cells are not scalable for widespread clinical use.

Purpose of the Study:

• To develop novel genetic engineering strategies to overcome HLA-mediated immune rejection of stem cell therapies.
• To create stem cell banks that can serve a larger proportion of the population.
• To generate universal donor stem cells for regenerative medicine.

Main Methods:

• Derived HLA-homozygous embryonic stem cell (ESC) subclones from heterozygous lines using gene targeting and mitotic recombination.
• Generated HLA class I-negative ESCs by disrupting the Beta-2 Microglobulin (B2M) gene.
• Utilized adeno-associated virus (AAV) vectors for efficient, nuclease-free gene targeting.

Main Results:

• A small bank of HLA-homozygous ESCs with common haplotypes could match a significant patient population.
• Differentiated B2M(-/-) ESCs showed reduced mixed leukocyte reactions and T cell responses.
• B2M(-/-) ESCs demonstrated potential as universal donor cells when HLA class II expression is absent.

Conclusions:

• Genetic engineering of ESCs offers a viable strategy to mitigate immune rejection in stem cell transplantation.
• HLA-homozygous and HLA class I-negative ESC lines represent promising advancements for allogeneic cell therapies.
• The developed methods yield pluripotent, transgene-free cell lines suitable for clinical translation.